肝动脉注射以THP-ADM为主的药物治疗不能手术切除的肝癌

THP－ADM（THP－Adriamycin，毗柔比星）是一种半合成的化学结构与ADM相近的葱环类抗肿瘤抗生素。实验研究表明其抗肿瘤活性与ADM相当或略高，副作用明显低于ADM。我们从1994年3月～12月采用肝动脉内注射以THP－ADM为主的药物治疗肝癌33例，现将其疗效及不良反应报告如下：1临床资料本组33例均为临床、影像学及病理学证实不能手术切除的肝癌。年龄26～75岁，男性27例，女性6例，Karnofsky评分均在70分以上。其中原发性肝癌27例，临床分期：Ⅱ期24例，Ⅲ期3例，AFP值有13例大于400ng／ml，4例大于200ng／ml，10例小于200ng／ml；…     

胰腺癌的诊治进展

 讲述了胰腺癌的特点；如何早期诊断；治疗原则与方法，包括各种有效的治疗手段，各自在综合治疗中的地位，特别是新的治疗方法与药物。对今后诊治的思路与方向进行了阐述。     

肺癌高发区化学预防研究

Since 1984, mass screening for cancer has been carried out in the realgar and tin mines, high incidence areas of lung cancer. Certain epidemical characteristics were found in precancerous lesion of lung cancer. Chemopreventive treatment were carried out by giving R1 [N-(p-ethoxycarbophenyl) retinamide] & R2 [N-(p-carboxyphenyl) retinamide]-retinoids synthesized by the Institute of Materia Medica, Chinese Academy of Medical Sciences. A prospective randomized double-blind control trial on the subjects with moderate or severe atypical hyperplasia cells in the sputum was conducted. Thirty-seven patients were treated by R1 (50 mg/d, p. o; total dose: 18.25 g/yr/case). In view of the absorption of R2 being better than R1, R2 (20 mg/d, p. o; total dose: 3.6/g/6mos/case) was given to 52 patients instead of R1. Patients in the control group were treated by riboflavin (50 mg/d, p. o.). The results showed that general status of the patients was improved. IgA and IgM in the serum were increased and the arsenic skin lesions were relieved after the treatment with R1 and R2. As compared with the control group, the incidence of lung cancer was 1:4 and mean degree of hyperplasia in the sputum dropped. It is suggested that these drugs are safe and effective in the chemoprevention of lung cancer. It is worth for further study.     

维生素甲类化合物的临床应用与前景

维生素甲类化合物(retinoids,简称维甲类)作为预防和治疗肿瘤的药物日益受到重视。实验表明维甲类能阻断癌遗传表型的表达,可抑制许多动物和人的恶性细胞类型的生长,且能诱导细胞分化。其作用机理虽未完全明瞭,但新近认为蛋白激酶C级联系     

食管癌的药物治疗

本文概述食管癌药物治疗的前景。恰当的治疗方案客观有效率在40％以上,1、3、5年生存率分别达42％,8.3％,7.1％。食管癌往往是多点发生的,由于有癌前病变(食管上皮重度增生)的病人,用药物治疗可取得良好效果,以及根据现代外科肿瘤学新概     

内分泌腺肿瘤与类癌的药物治疗

内分泌器官的肿瘤,临床表现往往比较复杂,既有恶性肿瘤、又有该肿瘤所分泌的生物学活性产物所致的症状和体征。治疗既要针对肿瘤,也要控制肿瘤分泌过多的产物。有关这方面的资料不多,为了提供临床参考,本文就此类肿瘤的药物治疗加以综     

EPR2或COME方案加放射治疗小细胞肺癌的疗效

小细胞肺癌(sclc)以CAV为代表标准联合化疗的效果已达坪期。化疗加放疗或“三明治”疗法以及辅助外科治疗已成为发展方向。鉴于顺铂(P)同足叶乙甙(E)联合治疗sclc有协同作用,为提高治疗效果,在以往经验的基础上,加用可抑制癌发生,既有抗致癌、又有抗促癌作用的维胺酸(R_2),设计两组化疗方案:即足叶乙甙+顺铂+维胺酸(EPR_2)或环磷酰胺+长春新硷+甲氨蝶呤+足叶     

青蒿素及其衍生物的抗肿瘤作用

青蒿素及其衍生物在体外对多种动物和人体肿瘤细胞具有抗瘤作用 ,对移植性动物肿瘤亦有确切的抑瘤效果 ,但其具体的作用机制尚不清楚 ,调控细胞周期的某一关键性的蛋白可能是其作用的靶点 ;青蒿素及其衍生物不仅与传统化疗药不存在交叉耐药 ,而且能逆转肿瘤细胞的多药耐药现象。通过深入研究其构─效关系及抗瘤作用机制 ,可望开发出高效、低毒、价廉、广谱的抗癌新产品。